Combination Treatment of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Symbiotic Effects on Metabolism and Cardiorenal Risk

INTRODUCTION: When treating type 2 diabetes, drugs that cause hypoglycemia and weight gain should, if possible, be avoided. In addition, due to the increased incidence and prevalence of cardiovascular disease, cardiac events and heart failure, as well as the accelerated renal decompensation that may...

Descripción completa

Detalles Bibliográficos
Autores principales: Goncalves, Edison, Bell, David S. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5984923/
https://www.ncbi.nlm.nih.gov/pubmed/29623594
http://dx.doi.org/10.1007/s13300-018-0420-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5984923/
https://www.ncbi.nlm.nih.gov/pubmed/29623594
http://dx.doi.org/10.1007/s13300-018-0420-6

Ejemplares similares